Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Deferred Taxes (2022 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Deferred Taxes for 4 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 209.89% to $7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.3 million through Dec 2025, up 75.08% year-over-year, with the annual reading at -$7.3 million for FY2025, 75.08% up from the prior year.
  • Deferred Taxes hit $7.4 million in Q4 2025 for Harmony Biosciences Holdings, up from -$3.9 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $7.4 million in Q4 2025 to a low of -$14.3 million in Q2 2024.
  • Historically, Deferred Taxes has averaged -$4.2 million across 4 years, with a median of -$4.3 million in 2022.
  • Biggest five-year swings in Deferred Taxes: crashed 697.68% in 2024 and later surged 209.89% in 2025.
  • Year by year, Deferred Taxes stood at -$4.3 million in 2022, then surged by 126.34% to $1.1 million in 2023, then plummeted by 697.68% to -$6.7 million in 2024, then soared by 209.89% to $7.4 million in 2025.
  • Business Quant data shows Deferred Taxes for HRMY at $7.4 million in Q4 2025, -$3.9 million in Q3 2025, and -$6.5 million in Q2 2025.